

FOSUN PHARMA
复星医药

2022



1

2

3

4

5

6



1/3

439.52

+12.66% YoY



139.38

+2.49% YoY



30%

25%



31.7%

38.73

+18.17% YoY



42.18

+7.10% YoY



MSCI-ESG

BBB

A

A



[®] **PD-1**
 MSI-H sqNSCLC ES-SCLC SCLC
 FDA EC
 MAA EMA *

[®]
 2022
[®] **CAR-T**
 10

13

III
 mRNA

[®]

RT002

III

SCLC

Tenapanor NHE3

*



[®]
 Parsabiv[®]

Organon
 Abbott

Eurofarma



Syneos Health
 PD-1

Gland
 Pharma
 Cenexi
CDMO
 Sisram

66%



GT1-GT6

CMC

Scientific Advisor
Board

SAB

5

®

2022

674

	2021	2022	YoY
	390.11	439.52	12.7%
	47.29	37.31	-21.1%
	32.77	38.73	18.2%
	39.38	42.18	7.1%
	49.78	58.85	18.2%
	38.37	43.02	12.1%
	1.85	1.43	-22.7%
()	30%	30%	-

	2021	2022
	48.1%	47.3%
	23.3%	20.9%
	8.3%	8.7%
	9.8%	9.8%
	1.2%	1.5%
	24.8%	26.4%

	2021	2022
	103.17	162.41
	391.96	445.82
	1.04	1.06
	0.85	0.85
	48.2%	49.5%

BNTX


-1.42
-10

15.93

BNTX

37.31

21.10%



2022 7
44.8

A
1
2

A



-

YoY 308.12 +6.60%
137.95
+28.04% YoY 2
34.13 * +29.77% YoY

Gland Pharma

6% Gland Pharma

mRNA
30%

YoY 69.49 +17.03%
15.21
+11.87%³ YoY 7.71
+2.33%³ YoY

Sisram

YoY 60.80 +33.56%⁴
1-6.22
2.55
-7.92 3.59




1
2
3
4

BNTX

2022

2021







/ADC RNA



ADC



RNAi

mRNA



CAR-&



&



CNS



02



01

03



50%

FIC+BIC



MSI-H ® PD-1

® CAR-T

® CD20

® HER2

®


®

®

®


® -

&





1/2



2/2








&

&BD&

:



&



, &BD






MSCI-ESG

A


2022

BBB
2021

BB
2020



 **E nvironment**



 **S ocial**



 **G overnance**








-

1

2



RNA

/ADC

BNTX

55.22 26%¹
+39.44% YoY

® HER2 ®
TNF- ® ®
PD-1


YoY 50.97 +13.62%
85%

16.54%

11.53% 35.52

30%

16 260 2022
48 249
PCT 17





SCLC

PD-1

3.4

2022

9



ES-SCLC

OS

OS

15.4

10.9

24

43.1%

7.9%



PD-1

MSI-H

SCLC FDA EC

JAMA

Nature Medicine

British Journal of Cancer

nature
medicine

JAMA
The Journal of the American Medical Association

BJC
British Journal of Cancer



27

110

30%

400

DTP

2022

13

2023 1



* 2022 11 III



Vero

20

13

Hi5
SF9



28



10+



40+




13
19A 19F 23F

2

III

1 3 4 5 6A 6B 7F 9V 14 18C




2022

10	5	mRNA [®]	
		HER2 [®]	
		CD20 [®]	
5	10	3	[®]
			[®]
3	5	8	[®] PD-1
			[®]
			[®]
			VERO
			8
1	3	31	[®] TNF-
			[®]
			[®]
			[®]
			31







2022



2022



2017
2019
2020
2021
2022

200 800
31.2

2016
2017
Xi

Intuitive Surgical

1,700 4,000



2022 55
300

10
2000 FDA 2022 12 31
7,544 55,000
1,000




Ion

2019 Ion
FDA
2021 10 Ion




Ion



2022







2011-2017



2018-2020



2021



6,333 *



JCI

JVF



2022



JCI国际认证医院
Organization Accredited
by Joint Commission International

21.45

1,750

1.11

86.47%



深圳恒生医院
SHENZHEN HENGSHENG HOSPITAL

2017 11
60%

9.09

600



湖北省人民医院
Hubei Provincial People's Hospital

900

2022 1

70%

800



宿迁市肿瘤医院
SUQIAN ZHONGYU HOSPITAL
宿迁市肿瘤医院
SUQIAN CANCER HOSPITAL



安徽济民肿瘤医院
ANHUI JIMIN CANCER HOSPITAL



温州老年病医院
WENZHOU GERIATRIC HOSPITAL



星家整形医疗美容
XINGJIA PLASTIC SURGERY & COSMETOLOGY





湖北省人民医院
Hubei Provincial People's Hospital



STAR
HOSPITAL
星晨妇儿

上海复星医疗旗下高品质医院
医保定点医院







			/		IND	1	2	3	NDA
	HLX10 ¹	+	PD-1						
				/					
		+	PD-1+VEGF						
		+HLX07	PD-1+EGFR						

2/2

		I		IND	1	2	3	NDA
	FS-1502	HER2	HER2					
			HER2					
	FS-1502+	HER2+PD-1	HER2					
	HLX14 ¹ 	RANKL						
	HLX26	LAG-3						
	HLX35 ² 	EGFR 4-1BB						
	HLX301	PD-L1 TIGIT						
	HLX15	CD38						
	HLX13	CTLA-4						
		EPO						
		INSR						
	50R	INSR						
		GLP-1						
	RT002		GL					
			CD					

2023 2 28

1/2


		I			IND	1	2	3	NDA
FCN-437c	CDK4/6	(1L)			2022	1	NMPA	III	I
		(2L)			2022	1		III	
SAF-189	ALK				2022	1	NMPA	III	I
	ROS1								
HLX-208	BRAF V600E		LCH	ECD	2022	1	NMPA	IIb/II	
FCN-159	MEK	I							
					2022	5	NMPA		
					2022	5	NMPA		
YP01001	VEGFR								
FCN-338	BCL-2								
		B							
FH-2001	FGFR/PD-L1								

2023 2 28

2/2

		I			IND	1	2	3	NDA
		TPO-R	ITP						
	Tenapanor	NHE 3	(ESRD-HD)						
		-							
	Tenapanor	NHE 3	(IBS-C)						
	FCN-342	URAT1							
	Molnupiravir	RNA							
	Paxlovid	3CL							
	BNT162b2	-							EUA
	PA-824	-	/	MDR-TB	XDR-TB	Pretomanid*			
	Opicapone	COMT				Ongentys*			
	Fortacin	-				*			
	ET-26	-							
					2022 7		II		

2023 2 28



%

LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and A 7 78 76 79A > 7 Fosun 3 6 , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.



www.fosunpharma.com